Covid 19 Vaccines in India

Corona Vaccine

Covid 19 Vaccines in India: India began administration of COVID-19 vaccines on 16 January 2021. As of 16 July 2021, India has administered over 399 million doses overall; including first and second doses of the currently-approved vaccines.

Covisheild and Covaxin – Covid 19 Vaccines

India initially approved the Oxford–AstraZeneca vaccine (manufactured under license by Serum Institute of India; under the trade name Covishield) and Covaxin (a vaccine developed locally by Bharat Biotech). They have since joined by the Sputnik V (manufactured under license by Dr. Reddy’s Laboratories) and Moderna vaccines
Covishield and Covaxin

On 1 January 2021, the Drug Controller General of India (DCGI) approved emergency use of the Oxford–AstraZeneca vaccine (local trade name “Covishield”).
On 2 January, the DCGI also granted an interim emergency use authorisation to BBV152 (trade name “Covaxin”); a domestic vaccine developed by Bharat Biotech in association with the Indian Council of Medical Research; and National Institute of Virology. This approval met with some concern, as the vaccine had not then completed
phase 3 clinical trials. Due to this status, those receiving Covaxin required to sign a consent form; while some states chose to relegate Covaxin to a “buffer stock” and primarily distribute Covishield.
The first phase of the rollout planned to target 30 million people, including 10 million healthcare workers; and 20 million frontline workers including police, paramilitary forces, sanitation workers, and disaster management volunteers.

Vaccination Program – Covid 19 Vaccines

India began its vaccination programme on 16 January 2021, operating 3,006 vaccination centres on the onset. Each vaccination centre will offer either Covishield or Covaxin, but not both. 165,714 people vaccinated on the first day of availability. Difficulties in uploading beneficiary lists at some sites caused delays.In the first three days, 631,417 people vaccinated. Of these, 0.18% reported side-effects and nine people (0.002%) admitted to hospitals for observation and treatment. Within those first days, there were concerns about low turnout; due to a combination of vaccine safety concerns, technical problems with the software used, and misinformation.

By 1 March, only 14 million healthcare and frontline workers had vaccinated, falling short of the original goal of 30 million.

Second phase

The next phase of the vaccine rollout covered all residents over the age of 60, residents between the ages of 45 and 60 with one or more qualifying comorbidities, and any health care or frontline worker that did not receive a dose during phase 1. second wave of infections in the country, vaccine exports suspended in March 2021, and the government ordered 110 million Covishield doses from SII. The company aims to produce 100 million doses per month, but by May 2021 its production capacity was only 60–70 million doses.Following the conclusion of its trial, the DCGI issued a standard emergency use authorisation to Covaxin on 11 March 2021

From 1 April, eligibility extended to all residents over the age of 45.On 8 April, Prime Minister Narendra Modi called for a four-day Teeka Utsav (“Vaccine Festival”) from 11 to 14 April, with a goal to increase the pace of the program by vaccinating as many eligible residents as possible. By the end of the Utsav, India had reached a total of over 111 million vaccine doses to-date.

Third phase

On 19 April, Liberalised Vaccination Policy under the 3rd phase was announced, to be started from 1 May. It extended the eligibility to all residents over the age of 18 and individual stakeholders were given more flexibility in how they conduct the vaccination programme. As part of this plan, only half of the vaccines procured by the Central Drugs Laboratory from manufacturers would be distributed by the central government. This supply would go to government-run clinics and be offered free-of-charge to residents 45 and over and priority workers, and siphoned off to states based on factors such as the number of active cases and how quickly they are administering vaccines.

While the book’s title and much of the writing concerns increasing income, the author insists that his philosophy can help people succeed in any line of work, to do and be anything they can imagine

India is on the thriving path to achieving the target of 50 crore doses to all the candidates/ citizens of India by July 31, this is crucial towards meeting our target coverage by end of this year,” stated by the report.

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *